US8088914B2ExpiredUtilityPatentIndex 49

MicroRNA and methods for inhibiting same

Assignee: STOFFEL MARKUSPriority: Apr 13, 2004Filed: Jul 6, 2009Granted: Jan 3, 2012

Est. expiryApr 13, 2024(expired)· nominal 20-yr term from priority

Inventors:STOFFEL MARKUS POY MATTHEW N TUSCHL THOMAS H

C12N 15/79C12N 15/113C12N 2310/141C12N 2310/331A61P 3/10C07H 21/02C12N 2310/531C12N 2330/10C12N 2320/51C12N 2310/322C12N 2310/314C12N 2310/3233C12N 2310/317C12N 2310/321

PatentIndex Score

Cited by

References

Claims

Abstract

The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.

Claims

exact text as granted — not AI-modified

1. An isolated nucleic acid molecule comprising a maximum of fifty moieties, wherein each moiety comprises a base bonded to a backbone unit, said molecule comprising the sequence of bases identified in SEQ. ID. NO. 8. 
     
     
       2. A molecule according to  claim 1 , wherein at least one of the moieties is a modified deoxyribonucleotide moiety. 
     
     
       3. A molecule according to  claim 2  wherein the modified deoxyribonucleotide is a phosphorothioate deoxyribonucleotide moiety. 
     
     
       4. A molecule according to  claim 2 , wherein the modified deoxyribonucleotide is a N′3-N′5 phosphoroamidate deoxyribonucleotide moiety. 
     
     
       5. A molecule according to  claim 1 , wherein at least one of the moieties is a modified ribonucleotide moiety. 
     
     
       6. A molecule according to  claim 5 , wherein the modified ribonucleotide is substituted at the 2′ position. 
     
     
       7. A molecule according to  claim 6 , wherein the substituent at the 2′ position is a C 1  to C 4  alkyl group. 
     
     
       8. A molecule according to  claim 7 , wherein the alkyl group is methyl. 
     
     
       9. A molecule according to  claim 7 , wherein the alkyl group is allyl. 
     
     
       10. A molecule according to  claim 6 , wherein the substituent at the 2′ position is a C 1  to C 4  alkoxy-C 1  to C 4  alkyl group. 
     
     
       11. A molecule according to  claim 10 , wherein the C 1  to C 4  alkoxy-C 1  to C 4  alkyl group is methoxyethyl. 
     
     
       12. A molecule according to  claim 5 , wherein the modified ribonucleotide has a methylene bridge between the 2′-oxygen atom and the 4′-carbon atom. 
     
     
       13. A molecule according to  claim 1 , wherein at least one of the moieties is a peptide nucleic acid moiety. 
     
     
       14. A molecule according to  claim 1 , wherein at least one of the moieties is a 2′-fluororibonucleotide moiety. 
     
     
       15. A molecule according to  claim 1 , wherein at least one of the moieties is a morpholino phosphoroamidate nucleotide moiety. 
     
     
       16. A molecule according to  claim 1 , wherein at least one of the moieties is a tricyclo nucleotide moiety. 
     
     
       17. A molecule according to  claim 1 , wherein at least one of the moieties is a cyclohexene nucleotide moiety. 
     
     
       18. A molecule according to  claim 1 , wherein the molecule is a chimeric molecule. 
     
     
       19. A molecule according to  claim 1 , wherein the molecule comprises at least one modified moiety for increased nuclease resistance. 
     
     
       20. A molecule according to  claim 19 , wherein the nuclease is an exonuclease. 
     
     
       21. A molecule according to  claim 20 , wherein the molecule comprises at least one modified moiety at the 5′ end. 
     
     
       22. A molecule according to  claim 20 , wherein the molecule comprises at least two modified moieties at the 5′ end. 
     
     
       23. A molecule according to  claim 20 , wherein the molecule comprises at least one modified moiety at the 3′ end. 
     
     
       24. A molecule according to  claim 20 , wherein the molecule comprises at least two modified moieties at the 3′ end. 
     
     
       25. A molecule according to  claim 20 , wherein the molecule comprises at least one modified moiety at the 5′ end and at least one modified moiety at the 3′ end. 
     
     
       26. A molecule according to  claim 20 , wherein the molecule comprises at least two modified moieties at the 5′ end and at least two modified moieties at the 3′ end. 
     
     
       27. A molecule according to  claim 20 , wherein the molecule comprises a cap at the 5′ end, the 3′ end, or both ends of the molecule. 
     
     
       28. A molecule according to  claim 27 , wherein the molecule comprises a chemical cap. 
     
     
       29. A molecule according to  claim 27 , wherein the molecule comprises an inverted nucleotide cap. 
     
     
       30. A molecule according to  claim 27 , wherein the nuclease is an endonuclease. 
     
     
       31. A molecule according to  claim 30 , wherein the molecule comprises at least one modified moiety between the 5′ and 3′ end. 
     
     
       32. A molecule according to  claim 30 , wherein the molecule comprises a chemical cap between the 5′ end and 3′ end. 
     
     
       33. A molecule according to  claim 1 , wherein all of the moieties are nuclease resistant. 
     
     
       34. An isolated nucleic acid molecule comprising a maximum of 500 moieties, wherein each moiety comprises a base bonded to a backbone unit, said molecule comprising the sequence of bases identified in the hairpin precursor of SEQ ID NO. 28. 
     
     
       35. An isolated nucleic acid molecule consisting of the sequence of bases identified in the hairpin precursor of SEQ ID NO. 28.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.